HIV-1-related Hodgkin lymphoma in the era of combination antiretroviral therapy: incidence and evolution of CD4⁺ T-cell lymphocytes

Julia Bohlius; Kurt Schmidlin; François Boué; Gerd Fätkenheuer; Margaret May; Ana Maria Caro-Murillo; Amanda Mocroft; Fabrice Bonnet; Gary Clifford; Vassilios Paparizos; Jose M Miro; Niels Obel; Maria Prins; Geneviève Chêne; Matthias Egger; Collaboration of Observational HIV Epidemiological Research Europe

doi:10.1182/blood-2010-08-301531

HIV-1-related Hodgkin lymphoma in the era of combination antiretroviral therapy: incidence and evolution of CD4⁺ T-cell lymphocytes

Julia Bohlius, Kurt Schmidlin, François Boué, Gerd Fätkenheuer, Margaret May, Ana Maria Caro-Murillo, Amanda Mocroft, Fabrice Bonnet, Gary Clifford, Vassilios Paparizos, Jose M Miro, Niels Obel, Maria Prins, Geneviève Chêne, Matthias Egger, Collaboration of Observational HIV Epidemiological Research Europe

76 Citationer (Scopus)

Abstract

The risk of Hodgkin lymphoma (HL) is increased in patients infected with HIV-1. We studied the incidence and outcomes of HL, and compared CD4⁺ T-cell trajectories in HL patients and controls matched for duration of combination antiretroviral therapy (cART). A total of 40 168 adult HIV-1- infected patients (median age, 36 years; 70% male; median CD4 cell count, 234 cells/ μL) from 16 European cohorts were observed during 159 133 person-years; 78 patients developed HL. The incidence was 49.0 (95% confidence interval [CI], 39.3-61.2) per 100 000 person-years, and similar on cART and not on cART (P = .96). The risk of HL declined as the most recent (timeupdated) CD4 count increased: the adjusted hazard ratio comparing more than 350 with less than 50 cells/μL was 0.27 (95% CI, 0.08-0.86). Sixty-one HL cases diagnosed on cART were matched to 1652 controls: during the year before diagnosis, cases lost 98 CD4 cells (95% CI, -159 to -36 cells), whereas controls gained 35 cells (95% CI, 24-46 cells; P < .0001). The incidence of HL is not reduced by cART, and patients whose CD4 cell counts decline despite suppression of HIV-1 replication on cART may harbor HL.

Originalsprog	Engelsk
Tidsskrift	Blood
Vol/bind	117
Udgave nummer	23
Sider (fra-til)	6100-8
Antal sider	9
ISSN	0006-4971
DOI	https://doi.org/10.1182/blood-2010-08-301531
Status	Udgivet - 9 jun. 2011

FN’s Verdensmål

Dette resultat bidrager til følgende verdensmål

Adgang til dokumentet

10.1182/blood-2010-08-301531

http://www.bloodjournal.org/content/bloodjournal/117/23/6100.full.pdf

Citationsformater

Bohlius, J., Schmidlin, K., Boué, F., Fätkenheuer, G., May, M., Caro-Murillo, A. M., Mocroft, A., Bonnet, F., Clifford, G., Paparizos, V., Miro, J. M., Obel, N., Prins, M., Chêne, G., Egger, M., & Collaboration of Observational HIV Epidemiological Research Europe (2011). HIV-1-related Hodgkin lymphoma in the era of combination antiretroviral therapy: incidence and evolution of CD4⁺ T-cell lymphocytes. Blood, 117(23), 6100-8. https://doi.org/10.1182/blood-2010-08-301531

Bohlius, J, Schmidlin, K, Boué, F, Fätkenheuer, G, May, M, Caro-Murillo, AM, Mocroft, A, Bonnet, F, Clifford, G, Paparizos, V, Miro, JM, Obel, N, Prins, M, Chêne, G, Egger, M & Collaboration of Observational HIV Epidemiological Research Europe 2011, 'HIV-1-related Hodgkin lymphoma in the era of combination antiretroviral therapy: incidence and evolution of CD4⁺ T-cell lymphocytes', Blood, bind 117, nr. 23, s. 6100-8. https://doi.org/10.1182/blood-2010-08-301531

@article{52d5d7a2a6cf4eae87e94cf1552129f2,

title = "HIV-1-related Hodgkin lymphoma in the era of combination antiretroviral therapy: incidence and evolution of CD4⁺ T-cell lymphocytes",

abstract = "The risk of Hodgkin lymphoma (HL) is increased in patients infected with HIV-1. We studied the incidence and outcomes of HL, and compared CD4+ T-cell trajectories in HL patients and controls matched for duration of combination antiretroviral therapy (cART). A total of 40 168 adult HIV-1- infected patients (median age, 36 years; 70% male; median CD4 cell count, 234 cells/ μL) from 16 European cohorts were observed during 159 133 person-years; 78 patients developed HL. The incidence was 49.0 (95% confidence interval [CI], 39.3-61.2) per 100 000 person-years, and similar on cART and not on cART (P = .96). The risk of HL declined as the most recent (timeupdated) CD4 count increased: the adjusted hazard ratio comparing more than 350 with less than 50 cells/μL was 0.27 (95% CI, 0.08-0.86). Sixty-one HL cases diagnosed on cART were matched to 1652 controls: during the year before diagnosis, cases lost 98 CD4 cells (95% CI, -159 to -36 cells), whereas controls gained 35 cells (95% CI, 24-46 cells; P < .0001). The incidence of HL is not reduced by cART, and patients whose CD4 cell counts decline despite suppression of HIV-1 replication on cART may harbor HL.",

author = "Julia Bohlius and Kurt Schmidlin and Fran{\c c}ois Bou{\'e} and Gerd F{\"a}tkenheuer and Margaret May and Caro-Murillo, {Ana Maria} and Amanda Mocroft and Fabrice Bonnet and Gary Clifford and Vassilios Paparizos and Miro, {Jose M} and Niels Obel and Maria Prins and Genevi{\`e}ve Ch{\^e}ne and Matthias Egger and Niels Obel",

year = "2011",

month = jun,

day = "9",

doi = "10.1182/blood-2010-08-301531",

language = "English",

volume = "117",

pages = "6100--8",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "23",

}

TY - JOUR

T1 - HIV-1-related Hodgkin lymphoma in the era of combination antiretroviral therapy: incidence and evolution of CD4⁺ T-cell lymphocytes

AU - Bohlius, Julia

AU - Schmidlin, Kurt

AU - Boué, François

AU - Fätkenheuer, Gerd

AU - May, Margaret

AU - Caro-Murillo, Ana Maria

AU - Mocroft, Amanda

AU - Bonnet, Fabrice

AU - Clifford, Gary

AU - Paparizos, Vassilios

AU - Miro, Jose M

AU - Obel, Niels

AU - Prins, Maria

AU - Chêne, Geneviève

AU - Egger, Matthias

AU - Collaboration of Observational HIV Epidemiological Research Europe

PY - 2011/6/9

Y1 - 2011/6/9

N2 - The risk of Hodgkin lymphoma (HL) is increased in patients infected with HIV-1. We studied the incidence and outcomes of HL, and compared CD4+ T-cell trajectories in HL patients and controls matched for duration of combination antiretroviral therapy (cART). A total of 40 168 adult HIV-1- infected patients (median age, 36 years; 70% male; median CD4 cell count, 234 cells/ μL) from 16 European cohorts were observed during 159 133 person-years; 78 patients developed HL. The incidence was 49.0 (95% confidence interval [CI], 39.3-61.2) per 100 000 person-years, and similar on cART and not on cART (P = .96). The risk of HL declined as the most recent (timeupdated) CD4 count increased: the adjusted hazard ratio comparing more than 350 with less than 50 cells/μL was 0.27 (95% CI, 0.08-0.86). Sixty-one HL cases diagnosed on cART were matched to 1652 controls: during the year before diagnosis, cases lost 98 CD4 cells (95% CI, -159 to -36 cells), whereas controls gained 35 cells (95% CI, 24-46 cells; P < .0001). The incidence of HL is not reduced by cART, and patients whose CD4 cell counts decline despite suppression of HIV-1 replication on cART may harbor HL.

AB - The risk of Hodgkin lymphoma (HL) is increased in patients infected with HIV-1. We studied the incidence and outcomes of HL, and compared CD4+ T-cell trajectories in HL patients and controls matched for duration of combination antiretroviral therapy (cART). A total of 40 168 adult HIV-1- infected patients (median age, 36 years; 70% male; median CD4 cell count, 234 cells/ μL) from 16 European cohorts were observed during 159 133 person-years; 78 patients developed HL. The incidence was 49.0 (95% confidence interval [CI], 39.3-61.2) per 100 000 person-years, and similar on cART and not on cART (P = .96). The risk of HL declined as the most recent (timeupdated) CD4 count increased: the adjusted hazard ratio comparing more than 350 with less than 50 cells/μL was 0.27 (95% CI, 0.08-0.86). Sixty-one HL cases diagnosed on cART were matched to 1652 controls: during the year before diagnosis, cases lost 98 CD4 cells (95% CI, -159 to -36 cells), whereas controls gained 35 cells (95% CI, 24-46 cells; P < .0001). The incidence of HL is not reduced by cART, and patients whose CD4 cell counts decline despite suppression of HIV-1 replication on cART may harbor HL.

U2 - 10.1182/blood-2010-08-301531

DO - 10.1182/blood-2010-08-301531

M3 - Journal article

SN - 0006-4971

VL - 117

SP - 6100

EP - 6108

JO - Blood

JF - Blood

IS - 23

ER -

HIV-1-related Hodgkin lymphoma in the era of combination antiretroviral therapy: incidence and evolution of CD4⁺ T-cell lymphocytes

Abstract

FN’s Verdensmål

Adgang til dokumentet

Fingeraftryk

Citationsformater